Spin crossover in mixed-anion Fe(NHtrz)(BF)(SiF) crystalline rod-shaped particles: the strength of the solid-liquid post synthetic modification.

A pure mixed-anion Fe(NHtrz)(BF)(SiF) spin crossover complex is obtained implementing a solid-liquid post synthetic modification approach from the Fe(NHtrz)(BF) parent complex. This method allows obtaining highly crystalline powder samples incorporating homogeneous micrometric (1 μm long) rod-shaped particles. This compound presents an abrupt spin crossover behaviour with a narrow (10 K) hysteresis loop centred just above room temperature (320 K) which makes it very interesting for future integration into devices for various applications.

Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. A 12-year experience.

Objective: To assess the efficacy of ursodeoxycholic acid (UDCA) in patients with intrahepatic cholestasis of pregnancy (ICP) and in the outcome of pregnancy.

Methods: Retrospective analysis of our 12-year experience treating ICP patients with UDCA. Thirty-two patients with pruritus starting before week 34 of pregnancy and with increased serum bile salts (BS) and alanine aminotransferase (ALT) received UDCA (15 mg/kg/day) for at least 3 weeks before delivery.

Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo.

Background/aims: Intense pruritus and the risk of stillbirths and premature deliveries justify the search for an effective pharmacologic treatment of intrahepatic cholestasis of pregnancy. This study was designed to test the efficacy of ursodeoxycholic acid in maternal pruritus, the biochemical abnormalities and the outcome of pregnancy, in patients with intrahepatic cholestasis of pregnancy of early onset.

Methods: Pregnant patients hospitalized in a secondary case-referral center with intense pruritus and abnormal serum levels of bile salts and aminotransferases, detected before week 33 of pregnancy, were randomly assigned to receive ursodeoxycholic acid, 1 g per day orally, or an identical placebo, until delivery, in a double-blind study.